The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Subscribe To Our Newsletter & Stay Updated
